Published Scientific Study Proves Efficacy of Eurofins Viracor-IBT’s ImmuKnow® Test, Improving Patient Survival Rate
11 June 2015 - 5:00PM
Business Wire
Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, is pleased to present the results from a recent study1
published in Transplantation, showing that Viracor-IBT’s ImmuKnow,
the FDA-cleared immune cell function assay that detects
cell-mediated immunity in immunosuppressed patients, helps improve
outcomes in solid organ transplant (SOT) patients. The study
demonstrated that the ImmuKnow assay provided additional data which
helped optimize immunosuppression, and ultimately improve patient
survival rate.
In solid organ transplantation, optimizing a patient’s
immunosuppressive therapy is critical in balancing the risk of
organ rejection caused by an inadequately suppressed immune system,
and the risk of infection, cancer and drug toxicity caused by
over-immunosuppression. Results from the study show the ImmuKnow
assay provides a useful biomarker which enables optimizing
immunosuppression to improve patient outcomes by preventing
bacterial and fungal infections, reducing immunosuppressant drug
use and improving 1-year patient survival. The use of the ImmuKnow
assay in a hospital’s immunosuppression protocol can therefore
increase the success rate in organ transplantation.
Specifically, the study showed that the use of the ImmuKnow
assay helped (1) increase patient survival by 13% one year
post-transplant (2) decrease infections over 2 weeks
post-transplant; and (3) lower immunosuppressant drug dosage
(tacrolimus). While there have been numerous retrospective and
prospective studies over the years demonstrating the ability of
ImmuKnow in identifying patients at risk of organ rejection and
infection, this is the first interventional, outcomes-based study,
which generated much discussion at the American Transplant Congress
(ATC) in May 2015.
Comment from Gilles Martin, Eurofins Scientific CEO: “The
ImmuKnow assay is just one of the specialized tests with fast
turnaround time that Viracor-IBT, part of the Eurofins Scientific
Group, offers to aid in the diagnosis and differentiation of SOT
complications. The findings of this study, particularly the
improvement in 1-year patient survival among transplant patients,
are encouraging, and illustrate the positive impact that Eurofins
aspires to across the Group. In line with its commitment to
contribute positively to health, Eurofins promotes innovation
across its laboratory network to develop technologies and
analytical methods that take scientific advancements to benefit
patients and consumers.”
1 Ravaioli M, Neri F, et al. Immunosuppression Modifications
Based on an Immune Response Assay: Results of a Randomized,
Controlled Trial. Transplantation. Epub* March 9, 2015.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150611005396/en/
Corporate CommunicationsJenni Miller, Phone: +1 800 305
5198
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024